Every material Form 8-K 20/20 Biolabs, Inc. has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
20/20 Biolabs, Inc. (AIDX) received a Nasdaq notice on September 3, 2026 saying it does not meet the $2,500,000 stockholders' equity requirement, based on its Form 10-Q showing $1,620,700 at June 30, 2026. The company has 45 calendar days to submit a compliance plan, and failing to regain compliance could bar it from the extra time it would otherwise get on the bid price issue, adding delisting risk for shareholders.
September 3, 2026: Nasdaq notice citing stockholders' equity of $1,620,700 versus a $2,500,000 requirement
Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 more days if accepted
Separate July 17, 2026 notice on the $1.00 bid price rule; compliance deadline is January 13, 2027
Missing the equity rule by January 13, 2027 would disqualify the company from a second bid price compliance period
In an investor webinar presentation furnished under Regulation FD, 20/20 Biolabs said Q2 2026 was its best quarter to date for cancer testing revenue, up 47% year over year. The presentation also described two preliminary, non-binding discussions with senior FDA personnel on August 25-26, 2026, which the company said did not constitute formal FDA feedback, concurrence or authorization.
Q2 2026 cancer testing revenue up 47% year over year, per the company's sales update
29 orders from new accounts; Maryland Firefighter Cancer Screening Program up more than 200% over 2025
Two in-person FDA discussions held August 25-26, 2026; company says no formal FDA feedback or authorization was given
Presentation used in the investor webinar held September 2, 2026 (Exhibit 99.1)
20/20 BioLabs reported second-quarter 2026 revenue of $0.7 million, up 36.5% from the prior year, and gross margin of 41.7%, up from 30.5%. Net loss widened to $1.5 million from $0.8 million, which the filing attributes partly to one-time Nasdaq listing costs and about $0.7 million in non-cash charges, and the company ended the quarter with $4.5 million in cash and no convertible note debt.
Q2 2026 revenue was $0.7 million, up 36.5% from $0.5 million; OneTest revenue rose 47.1% to $0.7 million.
Gross margin was 41.7% in Q2 2026, compared with 30.5% a year earlier.
Operating expenses rose to $1.5 million from $1.0 million, mainly from Nasdaq direct listing costs and product development.
Net loss was $1.5 million, versus $0.8 million, and cash and cash equivalents were $4.5 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every 20/20 Biolabs, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →